- Telehealth Visits
- Insurance plan information
Jeffrey Cheng, MD
Dermatology- Telehealth Visits
- Insurance plan information
Jeffrey Cheng, MD
Dermatology- Telehealth Visits
- Insurance plan information
On this page
Education & training
Board certification
- Dermatology, American Board of Dermatology
Residency
- Dermatology, University of CA at San Francisco School of Med
Internship
- Dermatology, Emory University School of Medicine
Degree
- MD, University of Texas Southwestern Medical School
My expertise
Specialties
Locations
My research
Clinical trials
Molecular Signatures of Cutaneous Dupilumab ResponseOpens in a new window
Recruiting
Change in EASI score from baseline to 8-12 weeks. Scores range from 0 to 72, with higher scores indicating more severity.
Publications
Showing 1-6 of 33 reviews
- February 19, 20265 out of 5 Stars
Dr. Cheng is very efficient and accommodating to the fact that I live 350 miles away from the clinic. He was extremely helpful and responsive in scheduling the appointment with only less than one week's notice that I would be traveling through San Francisco and fit me in.
- February 3, 20265 out of 5 Stars
Dr Cheng listened, discussed possible causes and possible treatments, and prescribed a stepwise approach that seems perfect.
- January 27, 20265 out of 5 Stars
Great! Pretty efficient / to the point, but fine with that! Seemed very skilled / knowledgeable.
- January 25, 20265 out of 5 Stars
Very professional and thorough
- January 23, 20265 out of 5 Stars
First time as a patient and all was superb
- January 2, 20264 out of 5 Stars
I didn't not receive some of the instructions or information in my Clinical Notes or After Visit Summary. I had to try to remember what he said and research some things on my own. Maybe the doctor was rushed and too busy.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.